Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy

Molecular Therapy

Volumn 23, Issue 4, 2015, Pages 757-768

  Jonnalagadda, Mahesh ^a   Mardiros, Armen ^a   Urak, Ryan ^a   Wang, Xiuli ^a   Hoffman, Lauren J ^a   Bernanke, Alyssa ^a   Chang, Wen Chung ^a   Bretzlaff, William ^a   Starr, Renate ^a   Priceman, Saul ^a   Ostberg, Julie R ^a   Forman, Stephen J ^a   Brown, Christine E ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN G4 FC SPACER; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG; CHIMERIC PROTEIN; IMMUNOGLOBULIN G; PROTEIN BINDING;

ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CHIMERA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; RECEPTOR BINDING ASSAY; T LYMPHOCYTE; THERAPY EFFECT; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MUTATION; NEOPLASMS, EXPERIMENTAL;

MUS;

ANIMALS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MICE; MUTANT CHIMERIC PROTEINS; MUTATION; NEOPLASMS, EXPERIMENTAL; PROTEIN BINDING; RECEPTORS, ANTIGEN; RECEPTORS, FC; T-LYMPHOCYTES;

EID: 84927098220     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.208     Document Type: Article

References (50)

1. Brentjens, RJ, Santos, E, Nikhamin, Y, Yeh, R, Matsushita, M, La Perle, K et al. (2007). Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13(18 Pt 1): 5426-5435.
2. Milone, MC, Fish, JD, Carpenito, C, Carroll, RG, Binder, GK, Teachey, D et al. (2009). Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17: 1453-1464.
3. Zhong, XS, Matsushita, M, Plotkin, J, Riviere, I and Sadelain, M (2010). Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/ AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 18: 413-420.
4. Haso, W, Lee, DW, Shah, NN, Stetler-Stevenson, M, Yuan, CM, Pastan, IH et al. (2013). Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121: 1165-1174.
5. Hudecek, M, Lupo-Stanghellini, MT, Kosasih, PL, Sommermeyer, D, Jensen, MC, Rader, C et al. (2013). Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19: 3153-3164.
6. Wilkie, S, Picco, G, Foster, J, Davies, DM, Julien, S, Cooper, L et al. (2008). Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 180: 4901-4909.
7. Guest, RD, Hawkins, RE, Kirillova, N, Cheadle, EJ, Arnold, J, O'Neill, A et al. (2005). The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 28: 203-211.
8. Savoldo, B, Ramos, CA, Liu, E, Mims, MP, Keating, MJ, Carrum, G et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptormodified T cells in lymphoma patients. J Clin Invest 121: 1822-1826.
9. Kebriaei, P, Huls, H, Jena, B, Munsell, M, Jackson, R, Lee, DA et al. (2012). Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 23: 444-450.
10. Wang, X, Naranjo, A, Brown, CE, Bautista, C, Wong, CW, Chang, WC et al. (2012). Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother 35: 689-701.
11. De Oliveira, SN, Ryan, C, Giannoni, F, Hardee, CL, Tremcinska, I, Katebian, B et al. (2013). Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. Hum Gene Ther 24: 824-839.
12. Huang, G, Yu, L, Cooper, LJ, Hollomon, M, Huls, H and Kleinerman, ES (2012). Genetically modified T cells targeting interleukin-11 receptor á-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res 72: 271-281.
13. Till, BG, Jensen, MC, Wang, J, Qian, X, Gopal, AK, Maloney, DG et al. (2012). CD20- specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119: 3940-3950.
14. Hudecek, M, Schmitt, TM, Baskar, S, Lupo-Stanghellini, MT, Nishida, T, Yamamoto, TN et al. (2010). The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116: 4532-4541.
15. Hombach, A, Wieczarkowiecz, A, Marquardt, T, Heuser, C, Usai, L, Pohl, C et al. (2001). Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 167: 6123-6131.
16. Mardiros, A, Dos Santos, C, McDonald, T, Brown, CE, Wang, X, Budde, LE et al. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122: 3138-3148.
17. Schroeder, HW Jr and Cavacini, L (2010). Structure and function of immunoglobulins. J Allergy Clin Immunol 125(suppl. 2): S41-S52.
18. Strohl, WR (2009). Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 20: 685-691.
19. Wang, X, Chang, WC, Wong, CW, Colcher, D, Sherman, M, Ostberg, JR et al. (2011). A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118: 1255-1263.
20. Hombach, A, Hombach, AA and Abken, H (2010). Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther 17: 1206-1213.
21. Wang, X, Berger, C, Wong, CW, Forman, SJ, Riddell, SR and Jensen, MC (2011). Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 117: 1888-1898.
22. Ishikawa, F, Yasukawa, M, Lyons, B, Yoshida, S, Miyamoto, T, Yoshimoto, G et al. (2005). Development of functional human blood and immune systems in NOD/SCID/ IL2 receptor {gamma} chain(null) mice. Blood 106: 1565-1573.
23. Ito, M, Hiramatsu, H, Kobayashi, K, Suzue, K, Kawahata, M, Hioki, K et al. (2002). NOD/SCID/gamma©(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175-3182.
24. Shultz, LD, Lyons, BL, Burzenski, LM, Gott, B, Chen, X, Chaleff, S et al. (2005). Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174: 6477-6489.
25. Reddy, MP, Kinney, CA, Chaikin, MA, Payne, A, Fishman-Lobell, J, Tsui, P et al. (2000). Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol 164: 1925-1933.
26. Sazinsky, SL, Ott, RG, Silver, NW, Tidor, B, Ravetch, JV and Wittrup, KD (2008). Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci USA 105: 20167-20172.
27. Heslop, HE, Stevenson, FK, and Molldrem, JJ (2003). Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program 2003: 331-349.
28. Brenner, MK and Heslop, HE (2010). Adoptive T cell therapy of cancer. Curr Opin Immunol 22: 251-257.
29. Gattinoni, L, Finkelstein, SE, Klebanoff, CA, Antony, PA, Palmer, DC, Spiess, PJ et al. (2005). Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202: 907-912.
30. Overwijk, WW and Schluns, KS (2009). Functions of γC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol 132: 153-165.
31. Berger, C, Jensen, MC, Lansdorp, PM, Gough, M, Elliott, C and Riddell, SR (2008). Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118: 294-305.
32. Gattinoni, L, Lugli, E, Ji, Y, Pos, Z, Paulos, CM, Quigley, MF et al. (2011). A human memory T cell subset with stem cell-like properties. Nat Med 17: 1290-1297.
33. Cieri, N, Camisa, B, Cocchiarella, F, Forcato, M, Oliveira, G, Provasi, E et al. (2013). IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121: 573-584.
34. Cartellieri, M, Bachmann, M, Feldmann, A, Bippes, C, Stamova, S, Wehner, R et al. (2010). Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol 2010: 956304.
35. Berger, C, Flowers, ME, Warren, EH and Riddell, SR (2006). Analysis of transgenespecific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107: 2294-2302.
36. Jensen, MC, Popplewell, L, Cooper, LJ, DiGiusto, D, Kalos, M, Ostberg, JR et al. (2010). Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 16: 1245-1256.
37. Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
38. Imai, C, Mihara, K, Andreansky, M, Nicholson, IC, Pui, CH, Geiger, TL et al. (2004). Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18: 676-684.
39. Kochenderfer, JN, Feldman, SA, Zhao, Y, Xu, H, Black, MA, Morgan, RA et al. (2009). Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 32: 689-702.
40. Gill, S, Tasian, SK, Ruella, M, Shestova, O, Li, Y, Porter, DL et al. (2014). Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123: 2343-2354.
41. Isaacs, JD, Greenwood, J and Waldmann, H (1998). Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function. J Immunol 161: 3862-3869.
42. Steplewski, Z, Sun, LK, Shearman, CW, Ghrayeb, J, Daddona, P and Koprowski, H (1988). Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 85: 4852-4856.
43. Nirula, A, Glaser, SM, Kalled, SL, Taylor, FR and Taylora, FR (2011). What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 23: 119-124.
44. Stoop, JW, Zegers, BJ, Sander, PC and Ballieux, RE (1969). Serum immunoglobulin levels in healthy children and adults. Clin Exp Immunol 4: 101-112.
45. Hudecek, M, Sommermeyer, D, Kosasih, PL, Silva-Benedict, A, Liu, L, Rader, C et al. (2014). The non-signaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res (epub ahead of print).
46. Nguyen, P, Moisini, I and Geiger, TL (2003). Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function. Blood 102: 4320-4325.
47. Kowolik, CM, Topp, MS, Gonzalez, S, Pfeiffer, T, Olivares, S, Gonzalez, N et al. (2006). CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66: 10995-11004.
48. Szymczak, AL, Workman, CJ, Wang, Y, Vignali, KM, Dilioglou, S, Vanin, EF et al. (2004). Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22: 589-594.
49. Jonnalagadda, M, Brown, CE, Chang, WC, Ostberg, JR, Forman, SJ and Jensen, MC (2013). Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy. PLoS One 8: e65519.
50. Stastny, MJ, Brown, CE, Ruel, C and Jensen, MC (2007). Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells. J Pediatr Hematol Oncol 29: 669-677.